16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; melanoma; cancer Mouse studies suggest an mRNA immunotherapy based on IL-36γ, IL-23 and OX40L could help treat colorectal cancer, melanoma and other cancers, including those resistant to checkpoint inhibitors. The therapy consists...
00:04 , Jan 31, 2019 |  BC Extra  |  Preclinical News

Moderna's triplet mRNA therapy treats checkpoint inhibitor-resistant tumors in mice

Moderna Inc. (NASDAQ:MRNA) published preclinical data Wednesday showing a triple mRNA combination product has efficacy against solid tumors, including those resistant to checkpoint inhibitors. The company's mRNA-2752 contains mRNAs encoding IL-23, IL-36γ and OX40L encapsulated...